search
Back to results

Empowering Patients to Better Manage Diabetes Through Self-Care

Primary Purpose

Type I or Type II Diabetes (Excludes Gestational Diabetes)

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Pharmacist Counseling
Educational materials
Sponsored by
Oregon State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type I or Type II Diabetes (Excludes Gestational Diabetes) focused on measuring diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: diabetes (Type I or Type II) enrolled in health plan with participating employer age 18 or older willing and able to provide informed consent Exclusion Criteria: gestational diabetes

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Usual Care plus out-of-pocket cost waiver

    EMPOWER

    Arm Description

    Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.

    Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.

    Outcomes

    Primary Outcome Measures

    Change in Hemoglobin A-1C From Baseline
    Compare changes in Hemoglobin A-1C from baseline between the two groups.

    Secondary Outcome Measures

    Changes From Baseline in LDL, HDL, Total Cholesterol, Triglycerides
    Changes from baseline in LDL, HDL, total cholesterol, triglycerides. Sample sizes for each individual test (usual care plus out-of-pocket cost waiver; EMPOWER group): LDL HDL Total cholesterol Triglycerides
    Changes in Economic Outcomes (Total Cost of Care, Cost of Diabetes Medications, Cost of Diabetes Supplies) From Baseline to 12 Months
    Changes in claims-based economic data on costs of total health care, diabetes medications, and diabetes supplies from baseline to 12 months. Only participants who had a claim in the 12 months prior to baseline were included in these analyses. The resulting sample sizes (usual care plus out-of-pocket cost waiver; EMPOWER group) for these outcomes are: Total cost of care Costs of diabetes medications Costs of diabetes supplies
    Change in Diabetes Knowledge and Empowerment (Patient Self-efficacy) From Baseline to 12 Months
    Psycho-social aspects of diabetes knowledge and empowerment. Sample sizes are in parentheses (usual care plus out-of-pocket cost waiver; EMPOWER group): Changes from baseline to 12 months for the Diabetes Empowerment Scale (DES). Mean score for 28 items each scored as a Likert scale from 1 to 5. Higher scores correspond to greater empowerment Changes from baseline to 12 months for the Adherence Starts with Knowledge (ASK-20) adherence barrier test total barrier score (TBC). The TBC has a range from 0 to 18 and higher scores correspond to greater barriers. Changes from baseline to 12 months for understanding of diabetes. This is a single question: "How would you rate your understanding of diabetes and its treatment?" which uses a 7-point scale Likert scale as the response from 1 (poor) to 7 (excellent).

    Full Information

    First Posted
    November 14, 2005
    Last Updated
    July 20, 2016
    Sponsor
    Oregon State University
    Collaborators
    Sanofi
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00254501
    Brief Title
    Empowering Patients to Better Manage Diabetes Through Self-Care
    Official Title
    Empowering Patients to Better Manage Diabetes Through Self-Care
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2005 (undefined)
    Primary Completion Date
    June 2011 (Actual)
    Study Completion Date
    June 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Oregon State University
    Collaborators
    Sanofi

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study will look at the impact of health insurance benefits on self management of diabetes for people with this condition. Studies have shown that when people with diabetes manage their disease better, they stay healthier. Our goal in this study is to help those with diabetes better manage their disease (self-care). We will compare two types of health insurance benefits in this study. We want to see if one set of benefits improves self-care more than the other one.
    Detailed Description
    The objective of this particular study is to determine if the addition of regular pharmacist visits to usual care can improve clinical outcomes in patients with diabetes. The central hypothesis is that a program overseen by community pharmacists that empowers patients to self-manage their diabetes will lead to improved clinical and humanistic outcomes and will be cost-effective. Strong preliminary data collected from other sites suggests that patient empowerment programs are effective at reducing hemoglobin A1C after 12 months and in reducing the total cost of care. This hypothesis will be tested by pursuing three specific aims to evaluate the impact of a pharmacist-administered diabetes patient empowerment program on: clinical markers for diabetes and related metabolic disorders; the cost of care and resource utilization; and patient knowledge and perceived ability to manage diabetes. There is an additional specific aim to assess the pharmacists with respect to satisfaction with the training program and the overall project, the activities conducted in patient sessions, and the time taken to complete the visits in this study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type I or Type II Diabetes (Excludes Gestational Diabetes)
    Keywords
    diabetes

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    69 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Usual Care plus out-of-pocket cost waiver
    Arm Type
    Active Comparator
    Arm Description
    Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
    Arm Title
    EMPOWER
    Arm Type
    Experimental
    Arm Description
    Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Pharmacist Counseling
    Intervention Description
    Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Educational materials
    Intervention Description
    Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
    Primary Outcome Measure Information:
    Title
    Change in Hemoglobin A-1C From Baseline
    Description
    Compare changes in Hemoglobin A-1C from baseline between the two groups.
    Time Frame
    baseline and 12 months
    Secondary Outcome Measure Information:
    Title
    Changes From Baseline in LDL, HDL, Total Cholesterol, Triglycerides
    Description
    Changes from baseline in LDL, HDL, total cholesterol, triglycerides. Sample sizes for each individual test (usual care plus out-of-pocket cost waiver; EMPOWER group): LDL HDL Total cholesterol Triglycerides
    Time Frame
    baseline and 12 months
    Title
    Changes in Economic Outcomes (Total Cost of Care, Cost of Diabetes Medications, Cost of Diabetes Supplies) From Baseline to 12 Months
    Description
    Changes in claims-based economic data on costs of total health care, diabetes medications, and diabetes supplies from baseline to 12 months. Only participants who had a claim in the 12 months prior to baseline were included in these analyses. The resulting sample sizes (usual care plus out-of-pocket cost waiver; EMPOWER group) for these outcomes are: Total cost of care Costs of diabetes medications Costs of diabetes supplies
    Time Frame
    baseline to 12 months
    Title
    Change in Diabetes Knowledge and Empowerment (Patient Self-efficacy) From Baseline to 12 Months
    Description
    Psycho-social aspects of diabetes knowledge and empowerment. Sample sizes are in parentheses (usual care plus out-of-pocket cost waiver; EMPOWER group): Changes from baseline to 12 months for the Diabetes Empowerment Scale (DES). Mean score for 28 items each scored as a Likert scale from 1 to 5. Higher scores correspond to greater empowerment Changes from baseline to 12 months for the Adherence Starts with Knowledge (ASK-20) adherence barrier test total barrier score (TBC). The TBC has a range from 0 to 18 and higher scores correspond to greater barriers. Changes from baseline to 12 months for understanding of diabetes. This is a single question: "How would you rate your understanding of diabetes and its treatment?" which uses a 7-point scale Likert scale as the response from 1 (poor) to 7 (excellent).
    Time Frame
    From baseline to 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: diabetes (Type I or Type II) enrolled in health plan with participating employer age 18 or older willing and able to provide informed consent Exclusion Criteria: gestational diabetes
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Dale F Kraemer, Ph.D.
    Organizational Affiliation
    Oregon State University, College of Pharmacy
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    21987530
    Citation
    Kraemer DF, Kradjan WA, Bianco TM, Low JA. A randomized study to assess the impact of pharmacist counseling of employer-based health plan beneficiaries with diabetes: the EMPOWER study. J Pharm Pract. 2012 Apr;25(2):169-79. doi: 10.1177/0897190011418513. Epub 2011 Oct 10.
    Results Reference
    result

    Learn more about this trial

    Empowering Patients to Better Manage Diabetes Through Self-Care

    We'll reach out to this number within 24 hrs